Closing AI drug-regulatory gaps through harmonized oversight
The article notes that while artificial intelligence accelerates drug discovery it also creates regulatory gaps, with more than 100 AI-assisted pipelines in trials and frameworks lacking enforceable standards; it therefore proposes a risk-tiered framework that distinguishes discovery AI from evidence-generating AI, mandates impact assessments and Investigational New Drug disclosure when AI influences decisions, and transforms guidelines into binding, risk-proportionate regulation.